1. Home
  2. BON vs KPRX Comparison

BON vs KPRX Comparison

Compare BON & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bon Natural Life Limited

BON

Bon Natural Life Limited

HOLD

Current Price

$1.18

Market Cap

9.9M

Sector

Health Care

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.55

Market Cap

11.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BON
KPRX
Founded
2006
1998
Country
China
United States
Employees
N/A
13
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9M
11.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BON
KPRX
Price
$1.18
$2.55
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
20.1K
23.2K
Earning Date
01-23-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$390.73
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$1.76
52 Week High
$3.39
$3.29

Technical Indicators

Market Signals
Indicator
BON
KPRX
Relative Strength Index (RSI) 45.17 47.67
Support Level $1.16 $2.47
Resistance Level $1.33 $2.58
Average True Range (ATR) 0.08 0.11
MACD -0.01 0.00
Stochastic Oscillator 33.33 40.62

Price Performance

Historical Comparison
BON
KPRX

About BON Bon Natural Life Limited

Bon Natural Life Ltd focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by its customers. It has developed four technology platforms for large-scale separation, safety improvement, activity enhancement, and functional compounding of natural products. The company's offerings include Fragrance compounds, Health supplements, and Bioactive food ingredients. The company generates revenue from the sale of its products, the majority derived from the sale of Fragrance compounds, which include natural compounds extracted from plants for cosmetic applications.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: